Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Empagliflozin + Linagliptin Tablets in Healthy Volunteers
NCT06932159Phase 1Completed
- Sponsor
- Humanis
- Start
- Dec 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin and linagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Humanis. Primary endpoints: Peak Plasma Concentration (Empagliflozin) at 72 hours, Area Under the Curve to last measurable concentration (Empagliflozin) at 72 hours and 2 more. Started Dec 2024; status: completed.
02
Drugs
empagliflozinlinagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06932159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06932159.